A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer
A Phase I-II Clinical Study of Nimotuzumab (TheraCIM h-R3) in Combination With External Radiotherapy in Stage IIB, III and IV NSCLC
Sponsor: CIMYM BioSciences
This PHASE1/PHASE2 trial investigates Non-small-cell Lung Cancer and is currently terminated or withdrawn. CIMYM BioSciences leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Mar 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CIMYM BioSciences
- YM BioSciences
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Calgary, Canada , Kelowna, Canada , London, Canada , Montreal, Canada , New Port Richey, United States , Ottawa, Canada , Québec, Canada , Singapore, Singapore , St. John's, Canada , Thunderbay, Canada and 1 more location